Podcast: Gene Therapy May Pack US FDA’s Calendar This Fall; CBER Staffs Up

Just as COVID-19 work begins to wane, CBER’s Peter Marks expects an influx of gene therapy work as sponsors attempt to salvage clinical trials.

Gene Editing_651647128_1200.jpg

The US Food & Drug Administration is preparing for a significant workload increase toward year-end as cell and gene therapy sponsors attempt to salvage or restart clinical trials affected by the COVID-19 pandemic – just as the work on the novel coronavirus starts to subside.

“In the latter part of this year, as the COVID response starts to dissipate and wind down, I’m concerned that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies